Does heaven exist? With well over 100,000 plus recorded and described spiritual experiences collected over 15 years, to base the answer on, science can now categorically say yes. Furthermore, you can see the evidence for free on the website allaboutheaven.org.

Available on Amazon
also on all local Amazon sites, just change .com for the local version (.co.uk, .jp, .nl, .de, .fr etc.)


This book, which covers Visions and hallucinations, explains what causes them and summarises how many hallucinations have been caused by each event or activity. It also provides specific help with questions people have asked us, such as ‘Is my medication giving me hallucinations?’.

Available on Amazon
also on all local Amazon sites, just change .com for the local version (.co.uk, .jp, .nl, .de, .fr etc.)


Female sexual dysfunction drugs

Category: Medicines


Involuntary and voluntary

Introduction and description


Sexual dysfunction drugs are a class of drugs invented to treat sexual dysfunction in women. 

The dysfunction – because this class of drugs was invented by men – is not wanting to have sex.

Sexual dysfunction in men is not being able to have sex because your willy won’t stand up long enough. 

It is somewhat interesting that in women, psychatrists have determined that the illness – since of course all women are able to have sex by simply being passive – is not wanting to have sex. 

There are many times I have not wanted to eat a fillet steak, preferring instead a bowl of soup.  Using the same logic I presumably had occasional bouts of fillet steak dysfunction.

The term invented to sell this class of drugs is called Hypoactive sexual desire disorder (HSDD).  It is defined as “a lack or absence of sexual fantasies and desire for sexual activity, as judged by a clinician”.  I should imagine the clinician has a most enjoyable time testing to make absolutely sure, ABSOLUTELY  sure that there is no desire at all.


For this to be regarded as a disorder, it must cause marked distress or interpersonal difficulties”. 

Distress for whom one wonders. 

HSDD only exists [as far as I am aware] in the USA.  It was listed under the Sexual and Gender Identity Disorders of the DSM-IV. In the DSM-5, it was split into male hypoactive sexual desire disorder and female sexual interest/arousal disorder. It was first included in the DSM-III under the name inhibited sexual desire disorder, but the name was changed in the DSM-III-R.

Interestingly, the only times in my youth that I can remember experiencing female sexual interest/arousal disorder was when I was either not attracted to the person I was with one iota, or I was attracted, but the man was so lacking in affection or consideration that he was a complete turn off.  In the end a selfish egotistical idiot, with about as much love and empathy in him as a block of concrete.  If my experience is any indicator therefore the real cause of HSDD is male ego inflation and a complete lack of love of or from a partner.

The psychiatrist should be treating the man.

But I suspect that what is happening is that the man says ‘what is wrong with you’ when the poor lass is unable to perform adequately for him with the same number of groans that he has seen on porn movies, and he packs her off to the doctor.  She, terrified does as she is told and is there diagnosed by the male clinician.


And from there she gets drugs…..

In 1987, when all these revisions to DSM-III, were made, the committee involved in revising the psychosexual disorders for the DSM-III-R estimated that about 20% of the US population had HSDD. 

I can only assume that they based their estimation on their own experiences, given that no research had been done on this at the time.  I’m surprised their figure was so low.

In 1970, Masters and Johnson published their book Human Sexual Inadequacy – but as far as they were concerned the only real dysfunctions were premature ejaculation and impotence for men, and anorgasmia and vaginismus for women. Anorgasmia is when one cannot achieve orgasm despite adequate stimulation.

In females it was then estimated at around 4.7 percent.  Given that at the time Masters and Johnson did their research, US men appeared to believe that female orgasm was achieved via vaginal, rather than clitoral, stimulation; one can only speculate that the majority of US women were masturbating to achieve sexual pleasure. 


Vaginismus is when involuntary vaginal muscle spasms make any kind of vaginal penetration painful or impossible, the website entitled vaginismus.com states that only 2 in 1000 women experience vaginismus.

So if we now sum up. 

As a result of a large number of men complaining that their wives did not seem interested in them and even read books and played with the remote control whilst they pumped up and down hoping for a vaginal orgasm, psychiatrists, keen to cash in on this new found problem decided that the best way to make money from it was to devise a new illness and a new class of drugs.

So, 30 or so years ago, HSDD was written into the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders [though in 2013, the term HSDD was replaced with a new term female sexual interest/arousal disorder (FSIAD).]  And the drug companies got working on it.


And from then on the drug companies have been publicising ‘surveys’ that appear to show the problem of FSIAD is indeed appalling. 

Suddenly it has escalated to unheard of levels. 

 According to one survey done by a supplier of drugs to treat this condition, of the 30 million women who are naturally menopausal in the USA, 3 million are distressed by their lack of sexual desire!

According to eHealthme, on the other hand, who collect Adverse Drug reports and other actual statistics on health, as of August 2015 there were a whopping ..........  35 cases of this in the USA at the moment.

In June 2016, eHealthme ceased to provide the information on which all the data in this section is based.  On querying my friends in the USA, it would seem that many of the sites that provided similar information, have done the same.  The links we provided to eHealthme also no longer work as this data too has been removed. 

As to why all these sites have removed exceptionally important information, my USA helpers said that more and more people are questioning what they are being given – and demanding to know WHY the CAUSE of their illness has not been investigated.  It appears that there has been a very heartening increase in the numbers of people who want to be healed – have the cause tackled and not the symptoms.  And this is ‘not popular’ with the conventional medical community, who cannot make money from well people.

The statistics collected from eHealthme remain valid for the date they were collected.  As such we have left this section as it is – an historical record.  Please read this section therefore only as an historical record of the figures that were applicable on the date specified.

Early drugs

Most of the early drugs were rebranded anti-anxiety and anti-depressants.  One favourite is the anti-anxiety/antidepressant, Bupropion ‘even in women who are not depressed’. 


Some doctors have also used various hormones, and even male impotence drugs like Viagra, Levitra, and Cialis

Tibolone (brand name Livial, Tibofem) is an HRT synthetic steroid drug with estrogenic, progestogenic, and weak androgenic action.  It has also been investigated as a possible treatment for female sexual dysfunction.

Some clinicians added Testosterone supplementation, with a logic that completely defeats me.
Its long term safety, however, is unclear.” 
Interestingly, one of the most common side effects experienced by taking pharmaceutical testosterone is that one becomes bedridden - this may explain why it is being prescribed. 

Although the arrhythmia, depression, rash, pain, fatigue, malaise, flushing, rectal bleeding, anger and arrhythmia [source eHealthme] accompanying the bedridden state may prove a little inconvenient.  Intrinsa was a testosterone patch designed to treat Female Sexual Dysfunction (FSD) in the USA.  In Australia, post-menopausal women are given Organon testosterone implants.

And we also have Bremelanotide under development as a treatment for and I quote “female sexual dysfunction (FSD), hemorrhagic shock, and reperfusion injury”.   An interesting combination.  “Bremelanotide was originally tested for intranasal administration in treating FSD but this application was temporarily discontinued in 2008 after concerns were raised over increased blood pressure seen with bremelanotide administration in some patients. As of December 201, a human phase III study is using a subcutaneous drug delivery system”.


Cabergoline and Pramipexole have at times been used off label as an adjunct to SSRI antidepressants in order to counter-act the side effects of those drugs, which are -  “reduced libido and anorgasmia”. 

The rationale for this is that the side- effects of pramipexole (and related D3-preferring dopamine agonist medications such as ropinirole) are and again I quote "compulsive gambling, punding, hypersexuality, and overeating, even in patients without any prior history of these behaviours". 

If we ignore for the moment the fact that you will now be so rotund from the overeating that your partner will not be able to get near you, we also have some other inconvenient side-effects from taking these drugs:

eHealthme - Most common Cabergoline side effects:

  • Mitral Valve Incompetence in Cabergoline (141 reports)
  • Pleural Effusion in Cabergoline (133 reports)
  • Aortic Valve Incompetence in Cabergoline (132 reports)
  • Hallucinations in Cabergoline (120 reports)
  • Breathing Difficulty in Cabergoline (102 reports)
  • Cardiac Failure in Cabergoline (96 reports)
  • Cardiac Valve Disease in Cabergoline (85 reports)
  • Oedema Peripheral in Cabergoline (78 reports)
  • Interstitial Lung Disease in Cabergoline (75 reports)
  • Fall in Cabergoline (72 reports)

Hopefully when you fall, the bed will be there to save you and you will be all ready, oxygen tank at hand to accept your partner's advances.

There are also drugs in the pipeline.  PF-219,061 is a “ potent and highly selective agonist for the dopamine D3 receptor” under development as a potential medication. UK-414,495 is a drug that breaks down the neuropeptide VIP. The consequent increase in VIP activity is claimed to “alter blood flow to the genital region leading to increased lubrication and muscle relaxation”.

Melanotan II was an experimental chemical that appeared to produce tanning.  Melanotan II produces bremelanotide, which, “is reported to be approximately 50-fold more potent as an inducer of sexual arousal in rats”. 


Despite the fact that rats are sexually aroused in ways somewhat different to human beings – being largely uninterested in naked rats or interesting lingerie, - these studies created a surge of interest with a rash of reports that Melatonin II had ‘aphrodisiac effects’

No product containing melanotan II has ever been approved for use by any governmental drug regulatory bodies, but despite this the product appears to be leaking out from somewhere and “Unlicensed and untested powders sold as melanotan II are being sold via the Internet.  Regulatory bodies have warned consumers the peptides are unsafe and ineffective”.

The story of Flibanserin

Flibanserin  is a drug that is being studied as a non-hormonal treatment for pre-menopausal women with hypoactive sexual desire disorder (HSDD).  Flibanserin is a 5-HT1A receptor agonist, D4 receptor very weak partial agonist/antagonist, and 5-HT2A receptor antagonist that had initially been investigated by Boehringer Ingelheim [Germany] as an antidepressant.  The company organised trials in the USA in order to receive FDA approval.


Two North American trials failed to demonstrate a statistically significant improvement on the co-primary endpoint of sexual desire. Therefore, neither study met the agreed-upon criteria for success in establishing the efficacy of flibanserin for the treatment of Hypoactive Sexual Desire Disorder.  The most commonly reported adverse events included dizziness, nausea, fatigue, somnolence and insomnia.

On June 18, 2010, a federal advisory panel to the U.S. Food and Drug Administration (FDA) unanimously voted against recommending approval of flibanserin. Earlier in the week, a FDA staff report also recommended non-approval of the drug. On October 8, 2010, Boehringer Ingelheim announced that it would discontinue its development of flibanserin in light of the FDA advisory panel's recommendation.

The rights to the drug were then transferred to Sprout Pharmaceuticals [USA], which is continuing the drug development process.

On June 27, 2013, Sprout Pharmaceuticals confirmed they had resubmitted flibanserin for FDA approval. On June 4, 2015, the panel to the FDA recommended approval of the drug by 18–6.

How it works

Why the hallucination?  Some of these hallucinations are caused by Serotonin imbalance - for those that are serotonin based.  Otherwise it is simpler to say one is being poisoned by toxins...... or simply poisoned.



References and further reading

The photos on this page are by Vollers corsets, 'suppliers of corsets to gentlewomen'.




 The figures below come from eHealthme and were derived from SEDA and FDA Adverse Drug reports submitted to doctors. The figures were correct as of mid August 2015.

In this table we can only give the number of hallucinations experienced for the drug as a whole, not the number directly attributable to its use in HSDD.

The link takes you to the eHealthme site, and the page on all the side-effects for that drug, including death.  We have not included the death figures here as we do not know whether death was being experienced by a woman with so-called HSDD.


No of hallucinations









Testosterone [Intrinsa]








Related observations